Prevention of arthritis-induced bone erosion by inhibiting osteoclast differentiation by the haloanilide n-methyl dichloropropionaniline
Ended Project Grant Awarded Last action
- Award ID
- R42AR074812
- Recipient
-
Exesalibero Pharma, Inc. UEI HVMJC4FQ8RM7
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,498,828
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date
- Originally
- Funding
-
- $2,103,889.00 Federal
- $394,939.00 Non-federal
- Place of performance
- West Virginia, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $394,939 | $0 | |
| Amendment | $394,939 | $394,939 | |
| Amendment | -$22,090 | $0 | |
| Amendment | $22,090 | $0 | |
| Amendment | -$22,090 | -$22,090 | |
| Amendment | $22,090 | $22,090 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,103,697 | $0 | |
| Amendment | $108,153 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $161 | $0 | |
| Original award | $102,000 | $0 |
Show all 17
Quick answers
Who received award R42AR074812?
R42AR074812 was awarded to Exesalibero Pharma, Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 25, 2019.
How much is award R42AR074812 worth?
$2,498,828 has been obligated on R42AR074812: $2,103,889 in federal funding and $394,939 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award